Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Spero Therapeutics (NASDAQ:SPRO).
August 06, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Spero Therapeutics.
An Overweight rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100